Influence of JAK2 46/1 haplotype in the natural evolution of JAK2V617F allele burden in patients with myeloproliferative neoplasms

Leukemia Research

Volumn 36, Issue 3, 2012, Pages 324-326

  Alvarez Larrán, Alberto ^a   Angona, Anna ^a   Martínez Avilés, Luz ^b   Bellosillo, Beatriz ^b   Besses, Carlos ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

Allele burden; Essential thrombocythaemia; JAK2 46 1 haplotype; JAK2V617F; Polycythaemia vera

Indexed keywords

ADULT; AGED; ALLELE; ARTICLE; CANCER GENETICS; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE; HAPLOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN CELL; JAK2 46 1 GENE; JAK2V61F GENE; MAJOR CLINICAL STUDY; MALE; MOLECULAR EVOLUTION; MOLECULAR GENETICS; MYELOPROLIFERATIVE DISORDER; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROSPECTIVE STUDY; THROMBOCYTHEMIA;

ADULT; AGED; ALLELES; BIOLOGICAL EVOLUTION; DNA, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HAPLOTYPES; HETEROZYGOTE; HOMOZYGOTE; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION; POLYCYTHEMIA VERA; PROGNOSIS; PROSPECTIVE STUDIES; REAL-TIME POLYMERASE CHAIN REACTION; THROMBOCYTHEMIA, ESSENTIAL;

EID: 84855956326     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.09.029     Document Type: Article

References (8)

1. Kilpivaara O., Mukherjee S., Schram A.M., Wadleigh M., Mullally A., Ebert B.L., et al. Germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat Genet 2009, 41:455-459.
2. Jones A.V., Chase A., Silver R.T., Oscier D., Zoi K., Wang Y.L., et al. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet 2009, 41:446-449.
3. Olcaydu D., Harutyunyan A., Jäger R., Berg T., Gisslinger B., Pabinger I., et al. A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet 2009, 41:450-454.
4. Vannucchi A.M., Antonioli E., Guglielmelli P., Longo G., Pancrazzi A., Ponziani V., et al. Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia 2007, 21:1952-1959.
5. Alvarez-Larran A., Bellosillo B., Martinez-Aviles L., Saumell S., Salar A., Abella E., et al. Postpolycythaemic myelofibrosis: frequency and risk factors for this complication in 116 patients. Br J Haematol 2009, 146:504-509.
6. Vannucchi A.M., Antonioli E., Guglielmelli P., Rambaldi A., Barosi G., Marchioli R., et al. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 2007, 10:840-846.
7. Silver R.T., Vandris K., Wang Y.L., Adriano F., Jones A.V., Christos P.J., et al. JAK2(V617F) allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy. Leukemia Res 2011, 35(2):177-182.
8. Besses C., Alvarez-Larrán A., Martínez-Avilés L., Mojal S., Longarón R., Salar A., et al. Modulation of JAK2 V617F allele burden dynamics by hydroxycarbamide in polycythaemia vera and essential thrombocythaemia patients. Br J Haematol 2011, 152:413-419.